Meet us in November in Boston or online from anywhere through our virtual platform for the global cardiovascular event of the year! Reconnect with colleagues, experience breakthrough cardiovascular basic, clinical and population science updates, and immerse yourself in innovative solutions designed to help you in your daily practice at the American Heart Association’s Scientific Sessions 2021.
- Enjoy instant access to leaders in the field and the latest discoveries in cardiovascular science and medicine.
- Reconnect and collaborate with global thought leaders from over around the world.
- Experience programming designed with your needs in mind with 27 programming communities.
- CE and MOC credits available.
- And more!
Don’t forget! AHA Professional Members receive the best rates for attending Scientific Sessions. Learn more about this and other benefits by becoming an AHA Professional Member.
The CLCD Council supports AHA objectives in clinical cardiology, promotes excellent clinical care, and fosters professional development and education for clinical cardiologists. Through council-sponsored symposia, panels, and scientific conferences, members can access and interpret new developments in the field and promote clinical cardiology to professional and lay audiences.
The CVSN Council accelerates the discovery, interpretation, and application of science to enhance cardiovascular health and treat cardiovascular diseases and stroke. The council helps develop scientific statements and advisories, guide professional education activities, provide scientific expertise, conduct research, translate findings, and promote evidence-based practices in clinical settings.
Victoria Delgado interviews investigator Marko Banovic about the results of the AVATAR trial, which he presented during Scientific Sessions 2021.
Norrina Allen, PhD, MPH, FAHA interviews Jiang He, MD, PhD, investigator for the Chinese Rural Hypertension Control Project, about the results of the study, which he presented during #AHA21.
Gregory M. Marcus, MD, MAS explains the methodology and results of the CRAVE trial, designed to assess the acute affects of coffee consumption in ambulatory patients.
Mina Chung, MD, FHRS discusses the results of the aMAZE trial with principal investigator David J. Wilber, MD, FAHA, FACC, FHRS. The trial examined percutaneous alternatives to the MAZE procedure for persistent AF.